Cancer Genetic Testing Market Size, Share & Trends Analysis Report By Type (Cytogenetic Testing/Chromosome Analysis, Biochemical Testing, Molecular Testing, DNA Sequencing), By Application (Lung Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Breast Cancer, Uterine Cancer), By End-Users (Hospitals and Clinics, Clinical Labs) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global cancer genetic testing market size was valued at USD 6.0 billion in 2023 and is projected to reach USD 16.1 billion by 2032, registering a CAGR of 11.6% during the forecast period (2024-2032). The rising incidence of breast and lung cancer is the key reason driving the increase of the cancer genetic testing market share over the predicted period.

Cancer genetic testing entails examining an individual's genetic material to detect any alterations or variations that may suggest a susceptibility to specific forms of cancer. Such Testing can aid in evaluating the likelihood of cancer development, directing individualized treatment strategies, and enabling timely identification. The cancer genetic testing market trends are ascribed to a growing emphasis on R&D of genetic Testing to study the correlation of cancer with the genetic sequence, an increase in hereditary cancer, and an increase in demand for DNA testing kits. However, rigorous regulations around cancer diagnosis may impede market expansion.

Highlights

• Molecular Testing commands the maximum share in the market based on type.
• Breast Cancer generates the highest revenue share in the market by application.
• Hospitals and Clinics are the major end-users of the market.

Market Dynamics

Global Cancer Genetic Testing Market Drivers

Rising Cancer Incidence

The global rise in cancer incidence has been a primary motivator for the implementation of cancer genetic testing. As cancer rates rise globally, there is an increasing demand for reliable screening and risk assessment technologies to enable early detection and individualized treatment regimens. For example, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. In 2023, cancer was responsible for around 9.6 to 10 million deaths worldwide. This equates to about 26,300 deaths every day due to cancer. This statistic is sufficient to demonstrate the severity and urgency of this condition.

The International Agency for Research on Cancer (IARC) predicts that the global cancer burden will increase dramatically in the future decades. The global cancer burden is anticipated to rise to around 30 million new cases by 2040, with the highest increases occurring in low- and middle-income nations. The rising incidence of cancer, including common kinds such as breast cancer, highlights the critical need for effective cancer prevention, early detection, and treatment. Genetic Testing is essential to identifying individuals more likely to acquire particular cancers, allowing for individualized screening and preventative measures.

Moreover, as cancer rates rise, so does demand for the cancer genetic testing market trend. More people, particularly those with a family history of cancer or other risk factors, are seeking genetic testing services to determine their susceptibility to the disease. This rising demand pushes advancements in testing methods, accessibility, and the creation of targeted medicines based on genetic insights.

Global Cancer Genetic Testing Market Restraints

High Cost and Affordability

The expense of genetic Testing, especially for comprehensive panels and modern technology, can be a considerable barrier to general use. Thorough genetic Testing frequently entails sequencing entire genomes or specific gene panels, which can be time-consuming and expensive. Affordability concerns may limit access to genetic testing services, particularly for those needing proper health coverage or financial resources. Genetic Testing, for example, can cost anywhere from USD 100 to more than USD 10,000, depending on its complexity and type. The cost is also determined by several criteria, including the type of test ordered and your personal and family history. 

Additionally, according to a study published in the Journal of Oncology Practice, the cost of genetic Testing for hereditary cancer syndromes varies greatly. According to the report, multigene panel testing can cost hundreds to thousands of dollars. The price burden connected with these tests may limit their accessibility, especially for those without adequate insurance coverage. The impact of excessive testing expenses is two-fold. For starters, it may prevent people from getting genetic tests, decreasing the ability to identify hereditary cancer risks. Second, it may add to healthcare disparities since people with limited financial resources may have difficulty getting these advanced genetic procedures.

Global Cancer Genetic Testing Market Opportunity

Integration with Oncology Practices and Healthcare Systems

Integrating cancer genetic testing into standard oncology practices and larger healthcare systems offers a tremendous opportunity to improve patient care and streamline the testing process. This integration can ensure that genetic information is seamlessly included in treatment decisions and risk assessments. 

A study published in the Journal of Clinical Oncology examined the effects of incorporating germline genetic testing into standard oncology care. The study discovered that integrating routine genetic Testing in an oncology environment boosted the detection of hereditary cancer disorders. The study found that 19.3% of patients evaluated had harmful germline mutations, emphasizing the importance of incorporating genetic Testing into standard oncology practices.

However, improving patient information and the availability of genetic testing are the first steps toward incorporating genetics into modern medical oncology treatment. Dr. Garber highlighted research published in the Journal of the American Medical Association (JAMA) in June 2023 that found that only 6.8% of more than 1 million cancer patients had germline genetic testing (an examination of inherited genes) within two years of diagnosis.

Incorporating genetic Testing into oncology practices ensures that genetic information becomes essential to patient care. Oncologists can use this data to make treatment decisions, identify those at a higher risk of hereditary malignancies, and propose appropriate preventive measures. This seamless connection helps to provide a more complete and tailored approach to cancer therapy.

Regional Analysis

The global cancer genetic testing market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global cancer genetic testing market shareholder and is estimated to grow at a CAGR of 11.8% over the forecast period. The United States is anticipated to create more money at the national level. In January 2022, the United States is predicted to have approximately 18.1 million individuals who have survived cancer, accounting for about 5.4% of the total population. Furthermore, it is projected that the number of individuals who have successfully overcome cancer will reach a staggering 22.2 million by the year 2030. The increasing utilization of sophisticated cancer treatment alternatives, combined with the escalating prevalence of cancer, has been a critical factor driving the expansion of the North American market.

Furthermore, in August 2020, the Dana Farber Cancer Institute established the Center for BRCA and Related Genes to prevent malignancies associated with BRCA mutations. Consequently, the market is expanding due to increased product approvals by the US Food and Drug Administration (FDA), and prominent companies focused on introducing innovative genetic testing products. Various factors, including disease awareness initiatives by the federal government, favorable reimbursement policies, increased demand for improved patient care, advancements in technology, a well-established medical infrastructure, and a growing elderly population, are driving the market growth in the North American region.

Asia-Pacific is anticipated to exhibit a CAGR of 12.3% over the forecast period. The Asia-Pacific region is projected to experience the most rapid growth during the projection period. The incidence of lung cancer in China has experienced exponential growth. Tobacco smoke exposure is a significant factor contributing to the rising incidence of lung cancer in the country. The Journal of Thoracic Oncology reports that lung cancer comprises 20% of all cancer diagnoses. Consequently, the need for genetic testing services specifically targeting cancer is on the rise in the region.

Moreover, the country's government prioritizes implementing policies to establish systematic cancer prevention and detection programs. As the country's population has grown, the likelihood of individuals being diagnosed with cancer has also risen over time. Moreover, most individuals have demonstrated a propensity for undergoing regular Testing. Consequently, the reliance on genetic testing programs designed explicitly for cancer is growing.

Europe's cancer genetic testing industry is undergoing substantial expansion due to breakthroughs in genetic technology, a rise in cancer incidence rates, and a growing awareness of customized medicine. Genetic Testing for different forms of cancer has been widely embraced in the region, leading to enhanced methods for diagnosing, selecting treatments, and assessing risks. The projected number of cancer deaths in the EU-27 for the year 2023 is 1,261,990. There has been a reduction of 6.5% in age-adjusted rates (ASRs) for males and a decrease of 3.7% for women. 

Additionally, Europe's Beating Cancer Plan, initiated in 2021, aims to enhance cancer prevention, treatment, and care within the European Union (EU). This plan encompasses European Union activities that specifically target cancer genetics. The research aims to ascertain an individual's genetic susceptibility to cancer development. The initiative additionally seeks to enhance the adoption of two crucial vaccinations that can effectively prevent viral infections that can potentially result in cancer. The immunizations encompass Human papillomaviruses (HPV) and Hepatitis B (HBV).

Segmental Analysis

The global cancer genetic testing market is segmented based on type, application, and distribution channel.

The market is further segmented by type into Cytogenetic Testing/Chromosome Analysis, Biochemical Testing, Molecular Testing, and DNA Sequencing.

Molecular Testing commands the maximum share of the market. Molecular Testing refers to a range of techniques that examine the structure and function of nucleic acids, such as DNA and RNA. Molecular-level Testing enables the identification of precise genetic mutations, changes, or anomalies. Polymerase chain reaction (PCR), quantitative PCR (qPCR), and reverse transcription PCR (RT-PCR) are prevalent techniques used in molecular diagnostics. Molecular Testing is crucial in finding genetic markers linked to hereditary disorders, infectious diseases, and cancer. It offers a comprehensive understanding of the genetic material, facilitating accurate diagnostics and tailored treatment strategies.

Biochemical Testing entails the examination of proteins, enzymes, or metabolites to evaluate their levels or activity, yielding insights into possible hereditary abnormalities. Such Testing frequently depends on analyzing blood or urine samples to quantify distinct biomarkers linked to specific medical disorders. Measuring the concentrations of particular enzymes in the blood can be utilized to diagnose metabolic diseases, such as phenylketonuria (PKU). Using biochemical Testing is beneficial for assessing the functional components of the body's biochemistry and detecting any anomalies that could signify underlying hereditary disorders.

The market can be bifurcated by application into Lung Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Breast Cancer, and Uterine Cancer.

Breast Cancer generates the highest revenue share in the market. Genetic Testing for breast cancer examines abnormalities in genes like BRCA1 and BRCA2, which greatly enhance the likelihood of developing breast cancer. Additional genetic variables linked to susceptibility to breast cancer may also be assessed. As per the National Breast Cancer Institute, breast cancer is projected to be the prevailing kind of cancer in the United States in 2023, with an approximate anticipation of 300,590 new instances. This accounts for around 30% of all newly diagnosed cases of cancer in females in the year 2023. Detecting genetic abnormalities in breast cancer aids in evaluating risk, allowing for customized screening, preventive measures, and tailored treatment choices for patients with hereditary risk factors. 

Lung cancer genetic Testing entails examining distinct congenital abnormalities linked to the formation and advancement of lung malignancies. Typically, mutations in the EGFR gene, which stands for epidermal growth factor receptor, are assessed to inform therapy choices, namely utilizing targeted medicines. Cancer.org predicts that in 2023, around 238,340 individuals will receive a diagnosis of lung cancer, and approximately 127,070 individuals will succumb to the disease. About 20% of lung cancer diagnoses are attributed to those who have never engaged in smoking, and it is projected that around 47,660 non-smokers will receive a lung cancer diagnosis in the year 2023. 

Based on distribution channels, the market is fragmented into Hospitals, Clinics, and Clinical Labs.

Hospitals and Clinics are the major end-users of the market. Genetic testing services are extensively available at hospitals and clinics, where healthcare professionals can request and conduct tests as a component of patient care. Hospitals and clinics play a crucial role in providing individuals with genetic Testing, particularly when these tests are incorporated into broader healthcare services. Genetic Testing at medical facilities is commonly carried out by interdisciplinary teams consisting of genetic counselors, oncologists, and other experts. The genetic test findings in these environments aid in making well-informed decisions about patient treatment plans and risk evaluations. Integrating genetic Testing into hospitals and clinics guarantees a smooth and effortless inclusion of this practice into regular medical care. This promotes cooperation among genetic counselors and other healthcare providers, allowing holistic patient care.

Clinical laboratories are essential in the genetic testing market since they function as specialized facilities with the necessary resources to perform various genetic tests. The laboratories receive samples, conduct tests, and provide comprehensive reports shared with healthcare practitioners and patients. Genetic Testing in clinical laboratories includes applying sophisticated techniques, such as PCR (polymerase chain reaction) and DNA sequencing, to examine genetic material. These laboratories may focus on specific categories of genetic Testing, such as cancer genetic testing or prenatal screening.

Impact of covid-19

The COVID-19 pandemic is likely to raise the demand for the lidocaine market, given the growing research and development activities in the market. For instance, in an article published by the U.S. National Library of Medicine in January 2021, a study was performed to study the impact of intravenous lidocaine on clinical outcomes of patients with Acute Respiratory Distress Syndrome ARDS during the COVID-19 pandemic. 

The purpose of the study was to evaluate the effects of intravenous lidocaine on inflammation and gas exchange in acute respiratory distress syndrome (ARDS) due to COVID-19 pneumonia. That increases the demand for lidocaine, thus propelling the market's growth. 

Recent Developments

• January 2024- The European Commission approved Roche's Tecentriq SC, making it the first subcutaneous injection of a PD-(L)1 cancer immunotherapy for numerous forms of cancer in the European Union.
• January 2024- QIAGEN Digital Insights introduced a very efficient next-generation sequencing (NGS) analysis method for detecting somatic cancer.
• February 2024- Myriad Genetics acquired Precise Tumor, Precise Liquid, and Laboratory from Intermountain Precision Genomics.